Arcus Biosciences (RCUS) Stock Looks Stretched As Casdatifan Trial Data Impresses

Arcus Biosciences has pulled back sharply in recent weeks, even though investors are still digesting fresh trial data and a sizeable equity raise. For anyone looking at the stock…

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)